Based on these observations, we investigated the possibility that the difference in clinical benefits between anti-PD-1/L1 and anti-CTLA-4 therapies in patients with MAP2K1/2-mutated melanoma can be used as a biomarker for the selection of the appropriate immunotherapy drug. This evidence concerns the gene CTLA4 and melanoma.